Oral Care Market (2026-2036)

The growth of this market is mainly driven by the rising global burden of oral disease, the shifting of fluoride delivery from municipal water supplies toward purchased products, strengthening World Health Organization policy commitment carrying dated 2030 targets, and the expanding older population and edentulism base. However, low and uneven treatment expenditure across income tiers, mature penetration and limited pricing power in developed markets, and regulatory restriction of consumer tooth whitening in the European Union restrain the growth of this market.

Furthermore, the rising requirement for independent efficacy substantiation, the expanding prescription and professional-strength product channels, and the growing addressable base in low- and middle-income markets are expected to offer growth opportunities for the stakeholders in this market. However, per- and polyfluoroalkyl substance restrictions eliminating conventional dental floss, non-monograph formulation exposing natural positioning to enforcement, concentrated product safety enforcement across the cosmetics regime, and packaging recyclability obligations falling on the laminate tube remain major challenges impacting the growth of this market. Additionally, the rising statistical and commercial separation of powered oral care from consumables, growing policy pressure on sugar consumption as a preventive lever, increasing divergence of fluoride policy across United States jurisdictions, and the expanding requirement for total fluorine calculation in European labelling are prominent trends in this market.

The oral care market comprises the consumer products used to clean, protect, treat and maintain the teeth, gums and oral cavity outside a clinical setting. The market includes toothpaste and dentifrice in paste, gel, powder and tablet form, manual and powered toothbrushes together with replacement brush heads, mouthwash and oral rinses in antiseptic, fluoride, cosmetic and therapeutic grades, dental floss and interdental cleaning products including picks and water flossers, consumer tooth whitening strips, gels, pens and devices, denture adhesives and cleansers, and breath fresheners and oral accessories such as tongue cleaners. The market is measured at manufacturer level on a product basis and counts both manufacturer brands and retailer own-brand supply. Professional and practitioner dental products are excluded, as are clear aligners, dental restorative materials, dental implants, chairside whitening systems, prescription dental therapeutics dispensed under a practitioner licence, and pet oral care. The market ecosystem extends from fluoride, silica, surfactant, humectant and polymer suppliers, laminate tube and bottle converters and brush bristle and motor suppliers through formulators, contract manufacturers and brand owners to grocery, pharmacy, convenience, e-commerce and subscription channels, dental practices that dispense and recommend, and the regulators, pharmacopoeial authorities and professional bodies whose monographs, cosmetic rules and seal programmes define what a product may claim.

The market is experiencing steady growth as the measured burden of oral disease has widened faster than treatment capacity has expanded. The World Health Organization fact sheet of 17 March 2025 places the number of people living with oral diseases at 3.7 billion, of whom an estimated 2.5 billion have untreated dental caries, comprising roughly 2 billion cases in permanent teeth and 510 million children with caries in primary teeth, while more than 1 billion people live with severe periodontal disease and oral cancers accounted for 389,846 new cases and 188,438 deaths in 2022. Edentulism affects about 7% of people aged 20 and above and rises to 23% among those aged 60 and above. The same assessment puts the global cost of oral conditions at USD 710 billion annually, split between USD 387 billion in direct treatment expenditure and USD 323 billion in indirect losses. A burden of that composition is addressed first through daily purchased prevention rather than through clinical intervention.

Demand for fluoride delivery through purchased products is strengthening as the municipal water route narrows across United States jurisdictions. Utah House Bill 81 took effect on 7 May 2025, prohibiting the addition of fluoride to public water systems and creating a pharmacist-dispensing pathway for fluoride supplements in its place, and Florida Senate Bill 700 followed on 1 July 2025 by removing fluoridation from the list of permitted water additives. The Environmental Protection Agency published a protocol for a fresh fluoride assessment on 3 August 2026 while the enforceable maximum contaminant level has stood unchanged at 4.0 milligrams per litre since 1986 and the Public Health Service recommendation of 0.7 milligrams per litre carries no enforcement weight. The Ninth Circuit vacated the Northern District of California judgment on 21 May 2026 under case number 25-384, leaving no judicial mandate in place. Each jurisdiction that withdraws fluoridation transfers a prevention function onto a product the household must buy.

Policy commitment has also moved from statements of intent toward dated, measurable targets that favour the preventive product. Resolution WHA74.5 on oral health was adopted on 31 May 2021, the global strategy was endorsed through decision WHA75(11) in 2022, the action plan was accepted through decision WHA76(9) in 2023, and the global oral health action plan was published on 26 May 2024 carrying eleven targets for 2030. The World Health Organization identifies exposure to fluoride toothpaste at a concentration of 1,000 to 1,500 parts per million as a primary caries control measure and lists affordable fluoride toothpaste among the interventions member states are expected to secure, a position reinforced by the inclusion of fluoride toothpaste on the Model List of Essential Medicines. Per-capita direct oral health spending of USD 0.52 in low-income countries against USD 260 in high-income countries shows where that target architecture has the furthest to travel. Procurement obligations framed this way convert a public health target into a measurable product requirement.

Company disclosure confirms that the category continues to compound while the source of that growth changes. Colgate-Palmolive reported oral care at 44% of worldwide net sales for the year ended 31 December 2025, against 43% in 2024 and 42% in 2023, which on disclosed consolidated net sales of USD 20,382 million equates to approximately USD 8,968 million. Haleon disclosed Oral Health revenue of GBP 3,461 million for 2025, up 7.9% on an organic basis and representing 31.4% of group revenue, and reported GBP 1,838 million for the first half of 2026 at 7.3% organic growth. Lion Corporation reported oral healthcare revenue of JPY 80,200 million for 2025, up 4.7%, rising 9.6% to JPY 40,535 million in the first half of 2026. The composition of that growth has shifted: Colgate recorded pricing of 2.1% against organic volume of negative 0.7% for 2025, moving to pricing of 1.6% and organic volume of 0.8% in the second quarter of 2026. Growth returning to volume reopens unit expansion as the route to market value.

Compliance obligations are simultaneously narrowing the formulation and packaging choices available to suppliers. Regulation (EC) No 1223/2009 governs oral care as cosmetics across the European Union, Commission Directive 2009/129/EC requires fluoride content to be declared as total fluorine across 20 named compounds listed at Annex III references 26 to 43, 47 and 56, and mandates two specified warnings on products containing 0.1% to 0.15% fluoride, while Council Directive 2011/84/EU confines hydrogen peroxide above 0.1% and up to 6% to practitioner-mediated sale and bars it entirely below age 18. In the United States, 21 CFR Part 355 fixes the permitted anticaries actives and caps package content at 276 milligrams of fluoride for dentifrices and 120 milligrams for gels and rinses. Maine prohibits intentionally added per- and polyfluoroalkyl substances in products naming dental floss from 1 January 2026, and Regulation (EU) 2023/2055 bans intentionally added microplastic abrasives with no transitional period. Each instrument removes a formulation option and redirects development spending toward compliant alternatives.

Alongside the consumable base, powered oral care is separating into a distinct commercial model built on device margin and consumable annuity. Published list pricing on one brand-owned store spans the Oral-B iO Series 10 at USD 399.99 and the iO Series 4 at USD 79.99, a fivefold spread within a single range, while replacement heads run from USD 5.00 each in an eight-count pack to USD 15.00 each for a two-count premium pack and the only subscription discount offered, at 20%, applies to heads rather than handles. A Waterpik Aquarius water flosser lists at USD 99.99 against mouthwash at USD 0.21 per fluid ounce and toothpaste at USD 1.38 to USD 1.95 per ounce. Portfolio movement follows the same logic: Church & Dwight exited the Spinbrush value powered line within an approximately USD 118.0 million group of divested businesses by the end of 2025, Haleon committed GBP 65 million to a dedicated oral health plant in Shanghai Lingang on 11 March 2026, and Perrigo placed its USD 354.4 million private-label oral care business under strategic review from the first quarter of 2026. Capital concentrating on therapeutic and powered positions raises the average realised value of each unit sold.

This reflects the reallocation of fixed shelf space toward fluoride and therapeutic positions as prevention responsibility shifts onto purchased products, which raises the realised value per linear foot and reduces the viability of marginal cosmetic variants.

This indicates that compliance-driven reformulation is absorbing development capacity without creating a chargeable consumer benefit, which compresses supplier margin and favours manufacturers with the scale to carry parallel formulation programmes.

This points to independent efficacy substantiation becoming a condition of professional recommendation, which advantages suppliers able to cite published clinical evidence or a recognised seal programme over those relying on footnoted internal comparisons.